click here for event slides and audio introduction to
TRANSCRIPT
Introduction to Extractables and LeachablesMichael Creese
Keith Scott
Smithers
March 2020
Click here for event slides and audio
Page 2 | © Smithers, 2020
Introduction • Your moderator: Rea Kongwa
• Proceedings
• Questions & Answers
• Technical issues: use chat feature
• Post event survey
Page 3 | © Smithers, 2020
Michael Creese• Manager, Chemical Analysis
• Michael manages Smithers’ Extractables and Leachables (E&L) and Chemical Analysis consultancy team in the UK. He has been working with E&L for over 11 years both for Biopharmaceuticals and Pharmaceuticals, and joined Smithers in 2009.
• Expertise: Extractables and Leachables, Chemical Analysis, Method Validation and Development
• Previously Michael worked in the validation department for one of the largest Single Use System suppliers and previous to that a petrochemical organization. He has used his expertise to solve the challenges of the assessment of extractables and leachables for Single Use System suppliers and users (bags, tubing, filters, connectors etc.) and Final Container Closure Systems (pMDIs, stoppers, vials, pre-filled syringes, cartridges etc.).
• Michael’s team supports a diverse range of clients and industries require the support of analytical experts working within a cGMP and ISO17025:2005 environment.
• Michael has a BSc in Chemistry, and is a Member of the Royal society of Chemistry (MRSC).
Page 4 | © Smithers, 2020
Keith Scott• Senior Project Manager
• Keith is part of Smithers’ Extractables and Leachables (E&L) and Chemical Analysis consultancy team in the UK. He has been working at Smithers for 37 years and with E&L for over 15 years.
• Expertise: Extractables and Leachables, Method Validation and Development
• Keith began being involved in managing E&L studies in 2003. In 2007 I became a commercial manager responsible for the Medical and Pharmaceutical sector, developing profitable relationships with new and existing clients to retain business and expand sales.
• In January 2018 he took up a Senior Project Manager role in the Extractables and Leachables (E&L) and Chemical Analysis consultancy team providing technical leadership for analytical testing services to external and internal clients and acting as subject matter expert on the design and delivery of technical packages of work.
• Qualifications
• Keith has a BSc in Chemistry, and an MPhil (Lancaster).
Page 6 | © Smithers, 2020
Outline• Definition of Extractables
• Definition of Leachables
• Why we undertake Extractable and Leachable testing
• Regulations and best practice guidelines
• Testing techniques
• An end of discussion Q&A.
Page 8 | © Smithers, 2020
Extractables
Organic or inorganic substances that can be released from components under laboratory conditions
• Accelerated / exaggerated temperatures, solvents or surface exposure
Page 9 | © Smithers, 2020
Leachables• Organic and inorganic substances that can be released from components used in the manufacture and storage of drug
products under conditions of normal use.
• Leachables are typically a subset of extractables or are derived from extractables.
Sources:
• Manufacturing / in-process / single use systems:
• Bioreactors, containers, storage bags, filters, tubing, gaskets, valves etc.
• Primary packaging components (in direct contact with the drug product):
• Vials, syringes/prefilled syringes, ampoules, bottles.• Closures (screw caps, rubber stoppers).
• Container liners.
• Secondary / tertiary packaging components:
• Cardboard containers.
• Overwraps, over seals.• Container labels (e.g. ink, adhesives).
Page 11 | © Smithers, 2020
Leachables - Why a Concern• Patient Safety
• Leachables can increase the toxicity of the drug product,
• through addition of toxic impurities
• Leachables can change the function/properties of the drug product
• Can reduce the drugs availability to the patient
• Biological drug products particularly susceptible
• Unfolding / denature and aggregation of proteins
Page 12 | © Smithers, 2020
Post Market Failures• Leachables can lead to:
• Drug product appearance change
• Particulates
• Colour change
• Odour
• Failure of related drug substance test methods
• Product recall
Page 16 | © Smithers, 2020
Regulatory Requirement• Food, Drug and Cosmetic Act - Section 501(a)(3)
• “a drug is deemed to be adulterated if its container is composed, in whole or part, of any poisonous or deleterious substance which may render the contents injurious to health…”
• 21 CFR Part 211.94 (a)
• “Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality or purity beyond the official or established requirements.”
Page 17 | © Smithers, 2020
Guidances Available• Packaging components should be constructed of materials that will not leach harmful or undesirable
amounts of substances to which a patient will be exposed when being treated with the drug product.”1
• “Equipment shall be constructed so that surfaces that contact components, in-process materials, or drug products shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.”2
1US FDA “Guidance for Industry: Container Closure Systems for Packaging Human Drugs, Biologics, Chemistry, Manufacturing and Controls Documentation”, May 19992US FDA, Code of Federal Regulations, 21CFR211.65
Page 19 | © Smithers, 2020
Standard Setting Organizations• United States Pharmacopeia (USP)
• The USP is the official pharmacopeia of the United States
• Aim to improve global health through standards and programs that ensure the quality, safety and benefit of medicines and food.
• Chapters numbered from <1000> to <1999> are considered to be interpretive, and are intended to provide information on, give definition to, or describe a particular subject
• USP chapters / monographs less than <1000> are enforceable.
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
• Brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of pharmaceutical product registration.
Page 20 | © Smithers, 2020
USP E&L Related Chapters
USP <1663>Extractables
USP <1664>, <1664.1>Leachables
USP <381>Elastomeric Closures for Injection *
<382> Functional
<1381> & <1321> Informational *
USP <1031>Biocompatibility of Materials *
<87> Biological Reactivity In Vitro *
<88> Biological Reactivity In Vivo *
USP <661>Plastics Packaging Systems and their
Materials of Construction *
<661.1> Materials
<661.2> Packaging Systems
<665> Manufacturing Systems *
<1661> & <1665> Informational *
• Official (under revision)• New (not official)
Page 21 | © Smithers, 2020
<1663> Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems
• Presents a framework for the design, justification, and execution of an extractables assessment for pharmaceutical packaging and delivery systems
• Establishes critical dimensions of an extractables assessment and discusses practical and technical aspects of each dimension
• Does not establish specific extraction conditions, analytical procedures, or mandatory extractablesspecifications and acceptance criteria for particular packaging and delivery systems or drug products
• Does not delineate every situation in which an extractables assessment is required
Page 22 | © Smithers, 2020
USP <1664> Assessment of Leachables Associated with Pharmaceutical Packaging Delivery Systems• Provides a framework for the design, justification and execution of a leachables assessment for pharmaceutical
packaging and delivery systems.
• Includes reference to USP <232> Elemental Impurities.
• USP <1664.1> Orally Inhaled Nasal Drug Products
• Considerations for leachables assessment in orally inhaled and nasal drug products (OINDP), including:
• Metered Dose Inhalers (MDIs);
• Nasal sprays;
• Inhalation solutions, suspensions, and sprays;
• Dry Powder Inhalers (DPIs).
• …to follow USP <1664.2> Parenteral and Ophthalmic Drug Products
Page 23 | © Smithers, 2020
Specific to medical devices• ISO 10993-12 - Sample preparation and reference materials
• ISO 10993-18 - Chemical characterisation of materials
• ISO 18562 - Contamination of breathing gas from gas pathways
Page 27 | © Smithers, 2020
Other Guidances of InterestBPOG (BioPhorum Operations Group)
• Collaboration of the major biopharmaceutical companies
• (taken from BPOG website)
Page 29 | © Smithers, 2020
Extractable and Leachable Stages• Risk assessment – identify components that require extractables data
• Extractable study
• Toxicological assessment of extractables
• Develop analytical methods for the determination of leachables
• Validate leachable methods
• Perform leachable time point analyses – 0, 3, 6, 12 months then yearly up to shelf life
• Extractable leachable-correlation shown
• Toxicological assessment of leachables
• Routine Extractables (leachables)
Component - routine batch release
Page 30 | © Smithers, 2020
Dosage Form - Leachable Risk / LikelihoodExamples of Packaging Concerns for Common Classes of Drug Products. (*)
Degree of Concern Associated with the Route of
Administration
Likelihood of Packaging Component-Dosage Form Interaction
High Medium Low
Highest Inhalation Aerosols and Solutions; Injections and Injectable Suspensions
Sterile Powders and Powders for Injection; Inhalation Powders
High Ophthalmic Solutions and Suspensions; Transdermal Ointments and Patches; Nasal Aerosols and Sprays
Low Topical Solutions and Suspensions; Topical and Lingual Aerosols; Oral Solutions and Suspensions
Topical Powders; Oral powders Oral Tablets and Oral (Hard and Soft Gelatin) Capsules
* U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CEDER) and Center for Biologics Evaluation and Research (CBER); Rockville, MD, Container Closure Systems for Packaging Human Drugs and Biologics; Guidance for Industry; May 1999; 1-41.
Page 31 | © Smithers, 2020
Risk Based -Extractable and Leachable Testing
2005 European Medicines Agency (EMEA) “Guideline on Plastic Immediate Packaging Materials”
Page 32 | © Smithers, 2020
Selection of Components for Assessment • Primary packaging -
• Direct contact with drug product:
• Secondary/tertiary packaging -
• Not in direct contact with drug product:
• Labels (inks, adhesives), external packaging –blister packs
• Manufacturing and and single use processing equipment -
• May contain vast number of components; filters, gaskets, tubing, bags…
Page 33 | © Smithers, 2020
Extractables Assessments Support• Characterisation of packaging / delivery systems / manufacturing components, and their various
materials of construction
• Development of safe and effective packaging/delivery systems and processes by assisting in the selection of components and materials of construction
• Understanding of effects of various manufacturing processes on packaging components and their potential leachables(e.g. sterilization)
• Determining the worst-case potential leachables profile which facilitates the development of leachables studies and the safety evaluation of potential and actual leachables
• Establishment of qualitative and quantitative leachables-extractables correlations
• Development of extractables specifications and acceptance criteria
• Investigation into the origin(s) of identified leachables whose presence causes out-of-specification results for a marketed product
Page 34 | © Smithers, 2020
Scope - Based on Scientifically Justified Thresholds• Both extractables and leachables should be guided by safety thresholds.
• The Safety Concern Threshold (SCT) is a “threshold below which a leachable would have a dose so low as to present negligible safety concerns from carcinogenic and noncarcinogenic toxic effects,” i.e., the default assumption was that leachables were all mutagenic in nature.
• 0.15 µg/day total daily intake for an individual organic leachable (inhalation drug products)
• 1.5 µg/day total daily intake for an individual organic leachable (parenteral/injectable drug products)
• In certain cases, a higher SCT could be justified based on such factors as duration of dosing. M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), March 2018
Page 35 | © Smithers, 2020
Scope - Based on Scientifically Justified Thresholds• The Qualification Threshold (QT) is the threshold
below which a given noncarcinogenic leachable is not considered for safety qualification (toxicological assessments) unless the leachable presents structure-activity relationship (SAR) concerns.
• 5 µg/day total daily intake for an individual organic leachable (for inhalation drug products).
• Variable for parenteral products depending on the chemical classification of the individual leachable (under FDA review).
• 5 µg/day is also the SCT for the sensitization/irritation toxicology endpoint.
5.00 6.00 7.00 8.00 9.00 10.0011.0012.0013.0014.0015.0016.0017.00
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
Time-->
Abundance
TIC: 1001020.D
Page 36 | © Smithers, 2020
Extraction Study Practical Considerations• Appropriate selection of extraction solvents, extraction conditions and preparation methods
• Use a wide range of analytical techniques – to cover the spectrum of extractables/leachables.
Generating the Extract Characterising the Extract
Page 37 | © Smithers, 2020
Design Aspects of an Extraction Study• The chemical nature of the extracting solvents
• The extraction time
• The extraction temperature
• The sample / solvent extraction ratios, final preparation stages
Page 38 | © Smithers, 2020
Extraction Intensity• Extraction conditions should allow completion in a reasonable time but should not be so aggressive as
to alter the nature of the resulting extractables profile.
• The most aggressive extraction conditions are reserved for the quantitative determination of chemical additive contents in components and materials.
Speed Integrity
Page 39 | © Smithers, 2020
Gentle versus Harsh ExtractionsThe Spectrum of Extraction “Intensity”
Exhaustive
HarshGentle
Actual Use Accelerated Vigorous
AggressiveDissolution/Digestion
Controlled Extraction
Studies
Simulation Studies
Page 40 | © Smithers, 2020
Extraction Solvent• The extracting power of polar aqueous
formulations consisting of soluble ingredients is driven primarily by drug product pH.
• Largely non-polar formulations can be readily simulated with organic solvents.
• “Aqueous” drug products containing stabilizers, solubilizing agents, and buffers, and products containing lipids, proteins, and peptides have a “polarity” that should be matched by the simulating solvent. Mixtures of miscible solvents (such as alcohol/water) can be used.
• Using multiple solvents with different “extracting powers” is appropriate for high risk dosage forms to best discover their potential leachables profiles.
Page 41 | © Smithers, 2020
Solvents• Solvents / oils can soften and swell the polymer
• Increased availability of migrating species within polymer
• Increased migration through the polymer
Polymer
Solvent
Page 42 | © Smithers, 2020
Further Considerations• Extraction / Solvent Ratios
• Extraction parameters consider the mass /surface area of the test article relative to the volume of the extracting solvent. Extraction ratios and preparation methods can be manipulated to facilitate the objective of the study meeting the required threshold limits for example the SCT.
• Final Extract Preparation
• Considers if any final filtration, concentration, dilution or liquid-liquid partition steps are required prior to analysis.
Soxhlet
Microwave
ASE
Reflux
Page 43 | © Smithers, 2020
Extraction Techniques
water condenser
soxhlet extractor
extraction flask
water condenser
air condenser
extraction flask
Shaking & sealed vessel
Sonication
Thermal Desorption / Headspace
Page 44 | © Smithers, 2020
Characterisation of Extractables• Objective
• To discover, identify and quantify all extractables present at levels greater than an established threshold. • Qualitative –
• Identifies extractables
• Quantitative –
• Confirms presence with reference external standards,
• Gives levels / amount present, • Uses optimised extraction conditions
(asymptotic levels)
• Extractable assessments should employ multiple analytical techniques
• ICP-MS
• ICP-OES
• ESI & APCI
• LC-UV
• LC-MS/MS
• LC-HRMS
• Library
• GC-MS
• GC-HRMS
• EI & CI
• Library
• GC-MS
• GC-HRMS
• Headspace
• EI & CI
• LibraryVolatile
Impurities
Semi-Volatile Impurities
Elemental Impurities
Non-Volatile
Impurities
Page 45 | © Smithers, 2020
Analysis of Extractables & Leachables
Page 46 | © Smithers, 2020
Extractables Identification Techniques
Technique Extractables
GC-MS Solvents, Low molecular weight monomers, initiators, antioxidants, UV absorbers, lubricants, process aids, plasticisers, anti-static agents, flame retardants, modifiers and oligomers.
LC-MS Medium to high molecular weight polar species including antioxidants, UV absorbers, plasticisers, lubricants process aids, heat stabilisers.
ICP Trace elements, catalysts, fillers etc … USP 232 elemental impurity limits
Gravimetry (Non volatile Residue (NVR))
Total non volatile extractable species
FT-IR on NVR Higher molecular weight oligomers, mould release agents e.g. silicone oil etc.
Page 47 | © Smithers, 2020
Gas Chromatography Mass Spectrometry (GC-MS)
8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
Time-->
Abundance
TIC: 42609016.D\data.ms
Total ion chromatogram of an HDPE nasal spray bottle
20 40 60 80 100120140160180200220240260280300320340
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/ z-->
Abundance
Scan 932 (12.663 min): 42609016.D\ data.ms (-912) (-)
97
57
41
82
125
140167 308182 207 280224 25226 346331
20 40 60 80 100120140160180200220240260280300320340
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/z-->
Abundance
#129888: 1-Docosene
57
97
41
82 308125
153
181 280196 223238 26526
unsaturated hydrocarbon a low molecular weight oligomer
50 100 150 200 250 300 350 400 450 5000
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
m/z-->
Abundance
Scan 2034 (20.437 min): 42609016.D\data.ms (-2012) (-)530
57219
147278
83 18929 107 474247 317 360 388 416 445 500
50 100 150 200 250 300 350 400 450 5000
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/z-->
Abundance
#186132: Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester530
57
219
83 147
189278111
29 474245501431359387317
Irganox 1076 a hindered phenolic polymer stabiliser
Page 48 | © Smithers, 2020
Liquid Chromatography Mass Spectrometry (LC-MS)
min5 10 15 20 25
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
MSD1 TIC, MS File (D:\SY73ED~1\DATA\BR0184\53209045.D) APCI, Pos, Scan, Frag: 100, "Scan 200-1250m/z"
Butylated hydroxytoluene (BHT) a stabiliser
Irganox 1010 a hindered phenolic polymer stabiliser
min5 10 15 20 25
0
2000000
4000000
6000000
8000000
MSD1 TIC, MS File (D:\SY73ED~1\DATA\BR0184\53209013.D) APCI, Neg, Scan, Frag: 150, "Scan 200-1250m/z"
m/z200 400 600 800 1000 1200
0
20
40
60
80
100
*MSD1 SPC, time=8.718 of D:\SY73ED~1\DATA\BR0184\53209013.D APCI, Neg, Scan, Frag: 150, "Scan 200-1250m/z"
Max: 2.63578e+006
21
9.3
22
0.2
m/z200 400 600 800 1000 1200
0
20
40
60
80
100
*MSD1 SPC, time=13.051 of D:\SY73ED~1\DATA\BR0184\53209045.D APCI, Pos, Scan, Frag: 100, "Scan 200-1250m/z"
Max: 132349
23
3.1
73
1.3
67
5.2
61
9.1
56
3.1
67
6.2
73
2.3
41
5.1
78
7.3
47
1.1
23
4.1
84
3.4
52
7.2
62
0.2
56
4.1
89
9.5
29
1.2
73
3.3
41
6.0
67
7.2
m/z200 400 600 800 1000 1200
0
20
40
60
80
100
*MSD1 SPC, time=13.104 of D:\SY73ED~1\DATA\BR0184\53209013.D APCI, Neg, Scan, Frag: 150, "Scan 200-1250m/z"
Max: 157952
11
75
.8
23
1.3
29
1.3
11
77
.8
23
2.2
29
2.3
26
1.2
Page 49 | © Smithers, 2020
Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES), Optical Emission Spectrometry (ICP-OES) or Mass Spectrometry (ICP-MS)
• Sample solutions are nebulised & introduced to plasma flame
• the emission rays which result (from the excited atoms returning to their natural state) are characteristic of a particular element
• MS detector – improves selectivity and
• sensitivity
• USP <232> specifies limits for the amounts of elemental impurities in drug products, serves a good base for scoping the extractables study. Thresholds are based on the specified permitted concentrations of the element which are dependant on root of administration.
Page 50 | © Smithers, 2020
Extractables Assessment Consensus• Volatile extractables by Headspace GC/MS; intact and dry materials or components.
• Multiple solvents with a range of polarities.
• Extracts should be characterised for:
• Volatiles and semi-volatile extractables by Direct Injection GC/MS.
• Non-volatile extractables by LC/UV/MS (positive and negative ion)
• Elemental extractables can be assessed in specially prepared acidic extracts by ICP/OES or ICP/MS
Page 52 | © Smithers, 2020
Objective• To rationalise the extractable list and provide a list of high priority extractables that should be targeted
during leachable studies.
• How?
• Based on a health risk assessment
• A toxicologist reviews and prioritises the identified extractables based on
• The chemical structure against potential toxic hazards / structural alerts
• Theoretical patient daily exposure against allowable daily patient exposures.
Output:• Some extractables will have negligible safety risk (safety assessment completed).• Some extractables may have unacceptable safety risk. Either packaging is rejected
or such extractables are established as targets for actual leachables studies
Page 54 | © Smithers, 2020
Leachable Overview and Study Goals• Leachables studies are accomplished as part of a drug stability program.
• To understand the trends in drug product leachable levels over the shelf-life of the product.• To determine maximum leachable levels up to the proposed shelf-life.• To characterise the leachables i.e. discovery, identification and quantification of leachables.
• Process Equipment Related Leachables (PERLs) can be determined in T=0 packaged product i.e. product set down, or taken from the first few product manufacturing batches.
• Analytical methods for leachables should be based on the analytical methods for extractables. • To help establish an extractable/leachable correlation.
• Qualitative correlation – Can be established if all of the leachables detected in a leachables study can be qualitatively linked either directly or indirectly to an identified extractable.
• Quantitative correlation – The leachables detected are demonstrated to be consistently less than the extractable which has been qualitatively correlated
• Test methods should be developed and validated.• To support a comprehensive safety evaluation of the drug product leachables.
• End goal • The collated leachable data permits a toxicological assessment to be made.
Page 55 | © Smithers, 2020
Leachables – the Analytical ChallengeLarge Volume Parenterals (LVPs)
• Consider an LVP with 1L of drug product packaged in a container/bag (20 g total weight of appropriate polymeric material), with a recommended dose of 1 container per day. For an individual organic leachable the estimated AET would be:
Estimated AET = 1.5 µ𝑔/𝑑𝑎𝑦
1 𝑏𝑎𝑔/𝑑𝑎𝑦× 1 𝑙𝑎𝑏𝑒𝑙𝑙𝑒𝑑 𝑑𝑜𝑠𝑒/𝑏𝑎𝑔
Estimated AET = 1.5 µg/bag = 1.5 ng/mL or 0.075 µg/g
• Low target concentrations in complex matrices can prove analytically challenging ...... and in some instances ‘simulated’ leachable studies are required.
Page 56 | © Smithers, 2020
Validation• Documented evidence to demonstrate that an analytical procedure, is suitable for its intended
purpose.
• Should follow industry accepted practices:
• ICH Q2 (R1) ‘Validation of Analytical Procedures: Text and Methodology’ guidelines.
• USP 1225 Validation of Compendial Procedures.
• A detailed validation protocol is prepared containing:
• Experimental details.
• Validation acceptance criteria
Page 57 | © Smithers, 2020
Validation Parameters to be considered• For quantitative testing of impurities:
• Instrument precision
• Linearity
• Method accuracy and repeatability
• Intermediate precision
• Specificity / resolution
• LoD and LoQ
• Range
• System suitability tests
• Robustness
Lot A’ Inverted
Lot A’ Upright
Lot A Inverted
Lot A Upright
• Metered Dose Inhaler drug product under accelerated storage. • Lot A’ - unwashed elastomeric components• Lot A - pre-washed elastomeric components
Page 58 | © Smithers, 2020
Example Leachables Trend Diagrams
Page 59 | © Smithers, 2020
Correlating Leachables and Extractables• Predicted Maximum Levels of Extractables and the Corresponding Leachables Following Storage for 18
months
Target Leachables Maximum Predicted Total Extractables
(µg/valve)
Drug Product Leachables (18 Month Inverted; 30 °C/70%RH)(µg/canister)
Lot A Lot B Lot C
Peroxide related leachables
3.2 2.4 0.9 0.7
Myristic acid 332 107 95.0 87.2Ethyl myristate <LOD 44.4 16.3 15.3
Palmitic acid 710 188 123 124Ethyl palmitate <LOD 111 67.9 54.5
Stearic acid 1230 289 184 165Ethyl stearate <LOD 113 60.9 70.2PBT dimer 5620 192 185 178PBT trimer 1810 20.6 20.1 19.2PBT tetramer 270 0.4 <0.4 0.6PBT pentamer 227 <LOD <LOD <LOD
Page 60 | © Smithers, 2020
Conclusions
• We all have the same goal… providing treatments to market: effectively, quickly, and assure patient safety.
EUROPEShawbury, ShrewsburyShropshireSY4 4NRUnited Kingdom +44 (0) 1939 250383
Cleeve RoadLeatherheadSurrey, KT22 7RUUnited Kingdom +44 (0) 1372 802000
NORTH AMERICA425 West Market StreetAkron, OH 44303+1 (330) 762-7441
6539 Westland Way, Suite 24Lansing, MI 48917+ (517) 322-2400
CHINABuilding #6A, 668 Fengting Road Suzhou Industrial Park (SIP) Jiangsu Province, China 215122+86 (0)512 6253 5581
Contact usContact our team with any questions or to request a quote
Page 61 | © Smithers, 2020
Michael CreeseManager of Project Management E: [email protected]: +44 (0) 1939 252 427
www.smithers.com/extractables-and-leachables
Keith ScottSenior Project ManagerE: [email protected]
T: +44 (0)1939 252422